VSAO JOURNAL Nr. 6 - Dezember 2018

PERSPEKTIVEN
Wirkstoff absolute KI relative KI
Diuretika (Thiazide) Gicht Metabolisches Syndrom
Glukoseintoleranz
Schwangerschaft
Hyperkalzämie
Hypokaliämie
Betablocker
Asthma
AV-Block Grad 2
AV-Block Grad 3
Metabolisches Syndrom
Glukoseintoleranz
Athleten und sportlich aktive
Patienten
Chronisch obstruktive Atemwegserkrankung
(ausser für vasodilatatorische
Betablocker)
Kalziumantagonisten
(Dihydropyridine)
Kalziumantagonisten (Verapamil,
Diltiazem)
ACE-Hemmer
Angiotensin-Rezeptor-Blocker
Mineralokortikoidrezeptorantagonisten
AV-Block Grad 2
AV-Block Grad 3
Trifaszikulärer Block
Hochgradige LV-Dysfunktion
Herzinsuffizienz
Schwangerschaft
Angioneurotisches Ödem
Hyperkaliämie
Bilaterale Nierenarterienstenose
Schwangerschaft
Hyperkaliämie
Bilaterale Nierenarterienstenose
Akute oder schwere Niereninsuffizienz (GFR < 30 ml/min)
Hyperkaliämie
Tabelle 7: Kontraindikationen bei antihypertensiver Therapie [8]
ACE: Angiotensin-konvertierendes Enzym; AV-Block: Atrioventrikulärer Block
Tachyarrhythmie
Herzinsuffizienz
Frauen im gebärfähigen Alter
Frauen im gebärfähigen Alter
ment of arterial hypertension: the Task Force
for the management of arterial hypertension
of the European Society of Hypertension
(ESH) and of the European Society of Cardiology
(ESC). Journal of hypertension 2013;
31: 1281 – 357.
9. Conroy RM, Pyorala K, Fitzgerald AP, et al.
Estimation of ten-year risk of fatal cardiovascular
disease in Europe: the SCORE project.
European heart journal 2003; 24:
987 – 1003.
10. Assmann G, Cullen P, Schulte H. Simple
scoring scheme for calculating the risk of
acute coronary events based on the 10-year
follow-up of the prospective cardiovascular
Munster (PROCAM) study. Circulation 2002;
105: 310 – 5.
11. D’Agostino RB, Sr., Vasan RS, Pencina MJ, et
al. General cardiovascular risk profile for use
in primary care: the Framingham Heart
Study. Circulation 2008; 117: 743 – 53.
12. Sehestedt T, Jeppesen J, Hansen TW, et al.
Risk prediction is improved by adding markers
of subclinical organ damage to SCORE.
European heart journal 2010; 31: 883 – 91.
13. Volpe M, Battistoni A, Tocci G, et al. Cardiovascular
risk assessment beyond Systemic
Coronary Risk Estimation: a role for organ
damage markers. Journal of hypertension
2012; 30: 1056 – 64.
14. Patel A, Group AC, MacMahon S, et al. Effects
of a fixed combination of perindopril and
indapamide on macrovascular and microvascular
outcomes in patients with type 2
diabetes mellitus (the ADVANCE trial): a
randomised controlled trial. Lancet 2007;
370: 829 – 40.
15. Appel LJ, Wright JT, Jr., Greene T, et al. Intensive
blood-pressure control in hypertensive
chronic kidney disease. The New England
journal of medicine 2010; 363: 918 – 29.
16. Wald DS, Law M, Morris JK, et al. Combination
therapy versus mono therapy in reducing
blood pressure: meta-analysis on 11,000
participants from 42 trials. The American
journal of medicine 2009; 122: 290 – 300.
17. ONTARGET Investigators, Yusuf S, Teo KK,
et al. Telmisartan, ramipril, or both in patients
at high risk for vascular events. The New
England journal of medicine 2008; 358:
1547 – 59.
18. Gupta AK, Arshad S, Poulter NR. Compliance,
safety, and effectiveness of fixed-dose
combinations of antihypertensive agents: a
meta-analysis. Hypertension 2010; 55:
399 – 407.
19. Prospective Studies Collaboration. Blood
cholesterol and vascular mortality by age,
sex, and blood pressure: a meta-analysis of
individual data from 61 prospective studies
with 55,000 vascular deaths. Lancet 2007;
370: 1829 – 39.
20. Chapman MJ, Ginsberg HN, Amarenco P, et
al. Triglyceride-rich lipoproteins and highdensity
lipoprotein cholesterol in patients at
high risk of cardiovascular disease: evidence
and guidance for management. European
heart journal 2011; 32: 1345 – 61.
21. Sever PS, Poulter NR, Dahlof B, et al. Antihypertensive
therapy and the benefits of
atorvastatin in the Anglo-Scandinavian
Cardiac Outcomes Trial: lipid-lowering arm
Nr. 6 Dezember 2018
VSAO JOURNAL ASMAC
51